Ostia Sciences Inc. Completes $1.46M Seed Round to Develop Microbiome Therapeutics Platform.
Ostia Sciences Inc., a microbiome therapeutics company developing next-generation probiotics, today announced the successful close of its seed financing round, raising CAD $1.46 million as of December 31, 2024.
Ostia Sciences Inc. Secures Over $1 Million CAD in Seed Investment Round, Finalizes IP Assignment with the University of Toronto, and Prepares First Prototype for Groundbreaking Microbiome Technology
Ostia Sciences Inc., a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, has successfully raised over CAD $1 million in its seed round and secured full intellectual property (IP) transfer from the university. “With full IP ownership and new funding, we’re ready to accelerate development of our SALI-10 probiotic,” added CSO Dr. Michael Glogauer. The company aims to close the round with an additional $700,000 by December 2024.
